Delivery Order SPE2DB20D2002-SPE2DB22FL13J
Award Date
1/14/22
Potential Completion Date
1/18/22
Potential Value
$176K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a specialty vaccine. The Firm Fixed Price contract has a ceiling value of $80,943.90 and an ultimate completion date of September 14, 2022. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which has a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the major pharmaceutical distribution company Amerisourcebergen Corporation, is for the provision of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine to the Defense Logistics Agency (DLA). The $1,577.28 fixed-price delivery order contract has a completion date of May 22, 2024. This award is associated with Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has a ceiling value of $67,356.00 and an ultimate completion date of October 21, 2021. This is a delivery order contract, with a firm fixed price pricing type. Amerisourcebergen Drug Corp is a subsidiary of the parent company...
This federal contract award, valued at $30,656.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a completion date of September 19, 2023. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop...
This federal contract award, valued at $23,574.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine, with a completion date of August 4, 2021. No set-aside designation was used for this award. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which specializes in pharmaceutical...
This federal contract award, valued at $1,778.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a pharmaceutical distribution company. The contract covers the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a medical product, with an ultimate completion date of October 25, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award has a ceiling value of $126,372.00 and is a firm fixed price delivery order contract, with a period of performance through January 7, 2025. The contract is not designated as a set-aside. AmerisourceBergen also holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The fixed-price delivery order, valued at $15,772.80, has a period of performance through March 8, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $28,154.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has a firm fixed price pricing type and an ultimate completion date of September 19, 2022. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,985.25 contract is a firm fixed-price delivery order for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award has an ultimate completion date of November 21, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...